4 Biotech Stocks Moving on Buyout Buzz

SNY stock has recently benefited from a round of short covering

Jan 22, 2018 at 10:58 AM
facebook twitter linkedin

Juno Therapeutics Inc (NASDAQ:JUNO) agreed to be bought out by Celgene Corporation (NASDAQ:CELG), confirming last week's reports in the Wall Street Journal. CELG already owns a 9.7% stake in JUNO, but will purchase the remainder of the company in an all-cash deal valued at roughly $9 billion, or $87 per JUNO share -- allowing it access to the Seattle-based firm's CAR-T cancer drug pipeline.

At last check, JUNO stock was trading up 27% at $86.09 -- earlier topping out just shy of the purchase price, at $86.28. CELG stock, on the other hand, is trading down 1% at $101.62. This downside isn't anything new for Celgene shares, which have shed roughly 26% in the past six months, and recent resistance forming at the stock's 60-day trendline.

In spite of CELG's technical troubles, put options have rarely been cheaper compared to their call counterparts. The stock's 30-day implied volatility skew of -1.4% ranks below 99% of all comparable readings taken in the past year.

Sanofi Will Pay $11.6 Billion for Bioverativ

Another biotech buyout making waves today is Sanofi SA's (NYSE:SNY) $11.6 billion all-cash bid for Bioverativ Inc (NASDAQ:BIVV), which works out to $105 per BIVV shares. The purchase will add Bioverativ's hemophilia treatments to the French drugmaker's rare disease portfolio.

BIVV stock is up 62.1% at last check to trade at $103.94, hitting a high of $104.30 in early trading. SNY, meanwhile, has plunged 3.9% to trade at $42.86, bringing its three-month deficit to 13.7%. More recently, the security's rally off its late-December lows was swiftly rejected by Sanofi's 60-day moving average, a trendline that helped usher the shares higher from April through June of last year.

Part of Sanofi's recent rebound was likely fueled by short sellers, with short interest down 22.92% in the most recent reporting period. However, this source of buying power is nearly depleted, considering it would take a little more than one session to cover the remaining shorted SNY shares.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners